OncoSec Medical (ONCS.OB) is rapidly advancing its IL-12 immunotherapy pipeline for the treatment of cancer which is also in multiple phase II trials. The company utilizes a novel electroporation approach to administer its IL-12 DNA plasmid to also instruct the targeted cells to express IL-12. Obtained from Inovio Pharmaceuticals (INO) via a licensing agreement in March of 2011, the electroporation administration platform appears to be a great fit for the IL-12 compound. Termed its ImmunoPulse technology, the device employs a handheld device comprised of six needles which are inserted into the tumor site. The needles are connected to an electrical generator that sends an electrical pulse through the six inserted needles which dramatically increases the permeability of the targeted tumor cell membranes. This electrical current allows previously-injected IL-12 DNA plasmid construct to rapidly enter the cells where it is trapped once the current is removed and the cells' membranes return to their previous state.
OncoSec currently has three phase II trials underway evaluating the effectiveness of ImmunoPulse to fight cancer, each launched in 2012. In February of 2012, the company launched its phase II trial addressing its largest targeted market group, metastatic melanoma. On November 15th, OncoSec reported interim data on the patient set. At the time of the interim analysis, 13 of 25 expected patients were enrolled and had been treated. 13 patients were evaluable at 39 days with 95% percent of treated lesions indicating response (14% stable disease (SD), 42% partial response (PR), 39% complete response (CR)). 9 patients were evaluable at 90 days with 100% of treated lesions indicating response (5% SD, 50% PR and 45% CR). Two patients were evaluable at day 180 with 100% of treated lesions indicating response (33% PR, 67% CR).
On March 25th of this year OncoSec reported its most recent trial update on the metastatic melanoma patient set. The data set analysis was on all lesions with partial or complete responses in order to ascertain durability of the treatment. Data indicated that 68% of the lesions had a durable response at three months with 45% of lesions having a durable response at six months - a seemingly robust response. According to the press release, OncoSec expects to complete enrollment in Q2 2013 with topline data expected in Q4 2013, a huge and significant event for the company's future.